Histone-modification studies using H3K4Me3 (active) and H3K27Me3 (repressive) antibodies in CD45⁺ hEBs. (A) Active HBE promoter marks are present in controls with a strong shift to repressive marks after Hh inhibition. (B) The HBG promoter shows active marks in both control and cyclopamine conditions, but has elevated repressive marks in control conditions. (C) The HBB promoter shows active marks after cyclopamine treatment only, with repressive marks observed in the control condition. (D) Positive control Gli1 promoter was repressed after cyclopamine treatment and uniquely displayed active marks in control conditions. (E) Negative control Nanog promoter exhibited repressive marks irrespective of treatment used for hEBs. Significance was measured with 1-tailed t tests. **P < .01; ***P < .001.